AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06503133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal yoga practice
Description: Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT06186622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Administered orally.
Study NCT04773964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET642
Description: MET642 active treatment
Study NCT04773964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT06416878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brief ES at the time of decompression for cauda equina syndrome
Description: In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
Study NCT06416878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brief ES to facilitate mcturition/removal of catheter
Description: In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
Study NCT05092828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine Injection
Description: In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
Study NCT05092828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Relieving
Description: Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
Study NCT06169696 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intervention/Treatment
Description: Non-invasive EEG headband device
Study NCT05669963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactoferrin
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Study NCT05669963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactoferrin
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Study NCT04847947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
Study NCT04847947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
Study NCT05443542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Game to be played is a commercially available VR game
Study NCT05443542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Sodoku, crossword puzzles
Study NCT05835934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK21542
Description: A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
Study NCT05711160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plaster models
Description: The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
Study NCT05711160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBCT images
Description: All patients have been undergoing CBCT scans for both jaws
Study NCT05103566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore
Description: Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
Study NCT06415877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Episio Training
Description: episio repair training
Study NCT06415877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Episio Training
Description: episio repair training
Study NCT06415877 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Episio Training
Description: episio repair training
Study NCT05371860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omit breast radiation
Description: Omit breast radiation for 3 years after surgery
Study NCT04770467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Description: BRII-196 and BRII-198 given by intravenous administration
Study NCT04770467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given by intravenous administration
Study NCT04770467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by intravenous administration
Study NCT06085612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Automated retinal oximetry
Description: Non invasive standard examination on automated retinal oximetry.
Study NCT05665829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake transnasal laser-assisted surgery (TNLS)
Description: The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
Study NCT05665829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaryngeal surgery (MLS)
Description: For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
Study NCT06102083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDI01 suspension
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.
Study NCT06102083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDI01 suspension
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.
Study NCT05653310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Tradipitant Capsule
Study NCT05653310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule
Study NCT05711160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOS images
Description: The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
Study NCT04817839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week post-operative activity restriction
Description: Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
Study NCT04817839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week post-operative activity restriction
Description: Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
Study NCT05656469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised medication advice based on pharmacogenetic testing
Description: Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
Study NCT05889793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emetine Hydrochloride
Description: To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
Study NCT05889793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant takes a placebo for 10 consecutive days.
Study NCT05209620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle).
Study NCT05209620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
Study NCT06215820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-02
Description: tablet
Study NCT06215820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: over-encapsulated tablet
Study NCT06215820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet
Study NCT06215820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet
Study NCT06436014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing VR experience
Description: Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
Study NCT05332392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00040
Description: Noninvasive wearable health monitoring device
Study NCT05680597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Tele-Rehabilitation Agility Boot Camp (ABC)
Description: The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
Study NCT06289426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
Study NCT05093569 — intervention group
Intervention type: DEVICE
Intervention: K'watch
Description: Patients
Study NCT05915104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX®
Description: 9 mg delayed and extended-release tablet once daily
Study NCT05915104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide controlled ileal release (CR) capsules
Description: three 3 mg capsules daily oral administration for 8 weeks
Study NCT05440344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.
Study NCT06242106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucometer
Description: A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
Study NCT06242106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer
Description: A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
Study NCT05685849 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
Study NCT05679440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural interventions based on pulmonary imaging
Description: The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
Study NCT00200889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TEAS
Description: non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
Study NCT05225792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promis Physical Function Questionnaire
Description: Patient reported physical function outcomes
Study NCT05225792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: L Test
Description: Performance based measure assessing general physical function and balance ability.
Study NCT05225792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrowing Beam Walking Test
Description: Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
Study NCT05225792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEQ-A
Description: Survey on confidence, stumbles and falls.
Study NCT06380725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation(real stimulation)
Description: Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
Study NCT06380725 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial alternating current stimulation(sham stimulation)
Description: Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
Study NCT05359276 — intervention group
Intervention type: DRUG
Intervention: Olipudase alfa
Description: GZ402665
Study NCT06417385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS soterix device
Description: Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
Study NCT05159687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
Study NCT05159687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
Study NCT05485701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening tools for common mental disorders
Description: A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
Study NCT05082792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: doppler ultrasound
Description: Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks
Study NCT05680597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Tele-Rehabilitation Agility Boot Camp (ABC)
Description: The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
Study NCT01996501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Orally Disintegrating 5mg Tablets
Study NCT05636683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root surface debridement
Description: subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
Study NCT05755932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFO MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA
Study NCT05755932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HFA MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA.
Study NCT05353894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 oral tablets and capsules
Description: Two formulations and Two dosage will be compared
Study NCT06025318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™
Description: PanCytoVir™ 100 mg/mL oral suspension
Study NCT05660356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Pfizer provided GH therapy
Study NCT05581927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Whole-Body Hypothermia
Description: patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
Study NCT05581927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard Whole-Body Hypothermia
Description: patients were allocated to standard Whole-Body Hypothermia